hdr isap

Polymyxin presentations 2013

Program for the 1st International Conference on Polymyxins
with links to the presentations

Thursday 2 May 2013

8:15 – 9:15


9:15 – 10:00

Roger Nation
Jian Li
SESSION 1: Welcome, program overview and introduction to the polymyxins

· Key features of the polymyxins
Roger Nation (30 min)

10:00 – 10:30

Morning tea, poster viewing and networking

10:30 – 12:30


David Paterson

Otto Cars

SESSION 2: The use of polymyxins in clinical practice

· Establishing the clinical need for polymyxins
David Paterson (25 min)

· Clinical outcomes in polymyxin studies: what are the challenges?
Fernanda Silveira (15 min)

· Are polymyxins effective? A meta-analysis of polymyxin use
Mical Paul (20 min)

· Snapshots of polymyxin use around the world:
12:30 – 13:45

Lunch, poster viewing and networking

13:45 – 15:45


John Turnidge

Dennis Dixon

SESSION 3: Towards optimized dosing of intravenous colistin and polymyxin B

·  Critical preclinical PK/PD information
Vincent Tam (15 min)

·  Intravenous polymyxins in critically-ill patients: how can we fit the dose to the patient?

    - Importance of the loading dose: CMS vs polymyxin B     

Lena Friberg (15 min)

     - Selection of individualized maintenance doses for various categories of patients: CMS vs polymyxin B    

Roger Nation (30 min)

· Dosing in other special patient populations
Helen Giamarellou (20 min)

· Risk factors for nephrotoxicity
Alan Forrest (10 min)

·  Managing patients with declining kidney function and other adverse effects
Visanu Thamlikitkul (20 min)

15:45 – 16:15

Afternoon tea, poster viewing and networking

16:15 – 18:00


Keith Kaye

Ursula Theuretzbacher

SESSION 4: What is the role of inhaled polymyxins for treatment of respiratory tract infections?

· Inhaled polymyxins: what can we learn from pulmonary delivery of other antibiotics?
Mike Dudley (20 min)

· Pulmonary disposition of polymyxins
William Couet (20 min)

·  Inhalational +/- intravenous administration of polymyxins for treatment of VAP
Helen Giamarellou (25 min)

· Use of polymyxins in patients with cystic fibrosis
Niels Høiby (25 min)

18:00 – 19:30

Reception on the Terrace

Friday 3 May 2013

9:00 – 11:00


Brian Tsuji

Fernanda Silveira

SESSION 5: Polymyxins: mono-therapy or a combination?

· Preclinical approaches: What is important – synergy or activity of combinations?
Brian Tsuji (20 min)

· Translational approaches to inform selection of rational combinations for patients
Juergen Bulitta (20 min)

· Clinical trials of monotherapy versus combinations
o   Colistin/fosfomycin      Visanu Thamlikitkul (20 min)
o   Colistin/rifampicin        Claudio Viscoli (20 min)
o   Colistin/carbapenems  Keith Kaye and Johan Mouton (10 min each)

11:00 – 11:30

Morning tea, poster viewing and networking

11:30 – 12:30


John Turnidge

Johan Mouton

SESSION 6: Susceptibility and breakpoints

· In vitro susceptibility testing: what are the critical issues?
John Turnidge (25 min)

· Polymyxin breakpoints: what needs attention?
Johan Mouton (25 min)

12:30 – 13:45

Lunch, poster viewing and networking

13:45 – 15:00




Robert Bonomo

Irene Plank

SESSION 7: Mechanisms of activity, resistance and nephrotoxicity: how understanding may be used advantageously

· Mechanisms of antibacterial activity
Brian Tsuji (20 min)

· Mechanisms of resistance
Robert Bonomo (20 min)

· Bacterial biofilm and resistance
Niels Høiby (15 min)

· Mechanisms of nephrotoxicity
Jian Li (15 min)

15:00 – 15:30

Afternoon tea, poster viewing and networking

15:30 – 16:30




Otto Cars

Vincent Tam


SESSION 8: Oral presentations of selected abstracts

· Abstract O-1
Murat Dizbay (8 min)

· Abstract O-2
Claudio Viscoli (8 min)

· Abstract O-3
Luisa Sorlí (8 min)

· Abstract O-4
Jason Pogue (8 min)
16:30 – 17:30




David Paterson

SESSION 9: Colistin and polymyxin B: are they peas in a pod or chalk and cheese?

A lively, entertaining and most importantly informative debate between two teams in which colistin and polymyxin B will be compared and contrasted. Might one have advantages over the other in regard to various considerations? The audience will have an opportunity to vote.

The topics are:

· The ability to achieve ‘appropriate’ plasma concentrations
Vincent Tam (Poly B team) vs John Turnidge (CMS team)

· Targeting specific infections (UTI, respiratory, CNS)
Matti Karvanen (Poly B team) vs William Couet (CMS team)

· Clinical effectiveness and adverse effects
Alexandre Zavascki (Poly B team) vs Keith Kaye (CMS team)

18:30 –

Conference dinner

Saturday 4 May 2013

9:00 – 10:00



Ursula Theuretzbacher William Couet

SESSION 10: Oral presentations of selected abstracts

· Abstract O-5
William Couet (8 min)

· Abstract O-6
Olivia Bargiacchi (8 min)

· Abstract O-7
Teysir Halaby (8 min)

· Abstract O-8
Gunther Kern (8 min)

10:00 – 10:30


Dennis Dixon
Irene Plank

SESSION 11: EU and NIH programs facilitating antibacterial resistance research

·  Outlines of the key programs of the NIH and EU will be provided
Irene Plank and Dennis Dixon

10:30 – 11:00

Morning tea and networking

11:00 – 12:30



Roger Nation
Jian Li

SESSION 12: The Prato Polymyxin Consensus

· Key topics and issues identified during the preceding symposia will be brought to this session and discussed by a panel, with ample opportunity for input from the audience

· Recommendations will be made on aspects impacting the future clinical use of polymyxins and high-priority areas for research, and the audience will be asked to vote on whether they do or don’t support the recommendations

· The outcome will be the basis of the Prato Polymyxin Consensus which will summarize high-priority areas requiring attention

Panel members:

David Paterson
Johan Mouton
Keith Kaye
Ursula Theuretzbacher
Brian Tsuji
Mike Dudley
John Turnidge

· The 2nd International Polymyxin Conference: when and where?

· Conference close

12:30 – 13:30

Lunch and departure to airport or other